In Situ Hybridization: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

SKU ID : WGR- 12990215

Publishing Date : 14-Mar-2018

No. of pages : 242

PRICE
4300
8600

  • The 2018 study has 242 pages, 83 tables and figures. Worldwide markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.

    In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).

    Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions.

    Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.

    In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations—the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target—the difference is the greater amount of information gained by visualizing the results within the tissue.

    The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

    Companies Profiled

    Market Leaders

    Leica Biosystems Nussloch GmbH
    Thermo Fisher Scientific
    F. Hoffmann-La Roche AG
    Abbott Laboratories
    Agilent Technologies
    PerkinElmer
    Qiagen / Exiqon A/S
    Merck KGaA
    BioGenex Laboratories
    BioTechne / Advanced Cell Diagnostics (ACD)

    Key Topics

    In Situ Hybridization
    Molecular Diagnostics
    Cervical Cancer Stain
    Fish Steps Reduction
    Fluorescence In Situ Hybridization (FISH)
    In Situ Hybridization (ISH)
    FISH Probe Kit
    Cancer
    Chromosonal Abnormalities
    Infectious Diseases
    Inflammatory Diseases
    Fluorescence In Situ Hybridization (FISH)
    Chromogenic In Situ Hybridization (CISH)
    Human Genetic Tests
    Microbial Tests
    In Vitro Diagnostics
    System for the Analysis of Solid Tumors
    Hybridization Technique
    Detection of Long Non-
    Coding DNA
    Coding RNA

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports